Investors focused on the Medical space have likely heard of Arcus Biosciences (RCUS - Free Report) , but is the stock performing well in comparison to the rest of its sector peers? Let's take a closer look at the stock's year-to-date performance to find out.
Arcus Biosciences is one of 896 companies in the Medical group. The Medical group currently sits at #1 within the Zacks Sector Rank. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. RCUS is currently sporting a Zacks Rank of #2 (Buy).
Over the past 90 days, the Zacks Consensus Estimate for RCUS's full-year earnings has moved 8.75% higher. This shows that analyst sentiment has improved and the company's earnings outlook is stronger.
Based on the latest available data, RCUS has gained about 38.32% so far this year. Meanwhile, the Medical sector has returned an average of -16.02% on a year-to-date basis. This shows that Arcus Biosciences is outperforming its peers so far this year.
To break things down more, RCUS belongs to the Medical - Biomedical and Genetics industry, a group that includes 385 individual companies and currently sits at #33 in the Zacks Industry Rank. On average, stocks in this group have lost 11.09% this year, meaning that RCUS is performing better in terms of year-to-date returns.
Investors with an interest in Medical stocks should continue to track RCUS. The stock will be looking to continue its solid performance.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Investors focused on the Medical space have likely heard of Arcus Biosciences (RCUS - Free Report) , but is the stock performing well in comparison to the rest of its sector peers? Let's take a closer look at the stock's year-to-date performance to find out.
Arcus Biosciences is one of 896 companies in the Medical group. The Medical group currently sits at #1 within the Zacks Sector Rank. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. RCUS is currently sporting a Zacks Rank of #2 (Buy).
Over the past 90 days, the Zacks Consensus Estimate for RCUS's full-year earnings has moved 8.75% higher. This shows that analyst sentiment has improved and the company's earnings outlook is stronger.
Based on the latest available data, RCUS has gained about 38.32% so far this year. Meanwhile, the Medical sector has returned an average of -16.02% on a year-to-date basis. This shows that Arcus Biosciences is outperforming its peers so far this year.
To break things down more, RCUS belongs to the Medical - Biomedical and Genetics industry, a group that includes 385 individual companies and currently sits at #33 in the Zacks Industry Rank. On average, stocks in this group have lost 11.09% this year, meaning that RCUS is performing better in terms of year-to-date returns.
Investors with an interest in Medical stocks should continue to track RCUS. The stock will be looking to continue its solid performance.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Get the latest research report on RCUS - FREE